BRISTOL-MYERS SQUIBB CANADA RELOCATES TO TECHNOPARC MONTREAL
Prominent R&D address to become new home for Canadian headquarters
MONTREAL, CANADA – (March 19, 2009) – Bristol-Myers Squibb Canada (BMS) will be calling Technoparc Montreal home as of March 23, 2009. The relocation of some 200 employees to its new national head office address in Canada's largest technological park is expected to be completed by month's end.
“The Technoparc was the optimal choice for us. As a true hub for R&D in Canada, the Technoparc reflects Bristol-Myers Squibb Canada's commitment to improving the health of Canadians through innovation,” said Wayne Quigley, President and General Manager of Bristol-Myers Squibb Canada. “Bristol-Myers Squibb has a longstanding history in Montreal and has called Saint-Laurent home for more than 50 years. We look forward to many more years at our new address.”
The BMS global vision is to extend and enhance human life through medical research, and the development and distribution of innovative medicines. With this move, Bristol-Myers Squibb renews its pledge to support Canadian healthcare professionals, patients and causes, and hopes to bring new vitality to the community and its economy.
BMS first established its roots in Canada more than 80 years ago with the incorporation of E.R. Squibb in 1925, while Bristol first opened its lab in Old Montreal in 1948. Bristol-Myers Canada expanded its activities through the acquisition of Squibb & Sons in 1989 and DuPont Pharmaceuticals in 2001. The Squibb plant, built in 1952 in Saint-Laurent, was until recently the Canadian head office for BMS. The relocation to the new Saint-Laurent home marks a new chapter in the future for BMS.
Bristol-Myers Squibb Canada's new address will be:
2344 Alfred-Nobel Boulevard, Suite 300
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Canada is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montreal, Quebec.